Novel compound for the treatment of sepsis and septic shock
University of Kansas
posted on 10/03/2005
Simple synthetic compounds of low toxicity have been identified for the treatment of sepsis and shock.
Researchers at KU Medical Center have developed synthetic cationic amphiphilic molecules to bind and sequester bacterial LPS and inhibit its toxicity in vitro and in vivo. Such molecules also appear to inhibit the deleterious effects of the administration of Gram-positive organisms, presumably by sequestration and subsequent neutralization of one or more species of molecules present in Gram-positive organisms that bear some physiochemical similarities to LPS.
-Low cost, effective, and broad-spectrum therapeutic agents for the treatment of sepsis and septic shock
-May enhance the effect of Gram-positive and/or Gram-negative sepsis or septic shock associated with septicemia
-The agents may enhance the effect of systemic antibiotic therapy by reducing or preventing pathological sequelae
AntiMicrobial Agents and Chemotherapy, April 1999, p.912-919The Journal of Infectious Diseases. 1997; 176:84-93Virology. 1998; 240: 118-126
File Number: 98KUMC177
Other Information: *State of Development* Available for license negotiations. *Testing* Animal studies have shown that these compounds prevent recognition of LPS by monocytes/macrophages, inhibit the production of inflammatory mediators, inhibit the induction of gene transcrition log LPS, and inhibit the production of endothelial derived nitric acid.
Find more innovations